Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4 , a novel once‐weekly basal insulin, in healthy participants: A randomized trial

Documenti analoghi

• The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects
  di: Yue Liu, et al.
  Pubblicazione: (2025)
• Pharmacokinetic properties of insulin GZR4 after subcutaneous administration in the thigh, abdomen, or upper arm in healthy participants
  di: Long Liu, et al.
  Pubblicazione: (2026)
• Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 1 diabetes
  di: Ulrike Hövelmann, et al.
  Pubblicazione: (2024)
• Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China
  di: Xichen Tong, et al.
  Pubblicazione: (2026)
• Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the ONWARDS 1–5 trials
  di: Peter Rossing, et al.
  Pubblicazione: (2025)